Telavancin Hospital-Acquired Pneumonia Trials: Impact of Gram-Negative Infections and Inadequate Gram-Negative Coverage on Clinical Efficacy and All-Cause Mortality

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S87-S93

  Lacy, Melinda K ^a   Stryjewski, Martin E ^b   Wang, Whedy ^a   Hardin, Thomas C ^a   Nogid, Boris ^a   Luke, David R ^a   Shorr, Andrew F ^c   Corey, G Ralph ^d   Barriere, Steven L ^a  

^a THERAVANCE INC   (United States)

^b Centro de Estudios Médicos e Investigaciones Clínicas norberto Quirno   (Argentina)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

ATTAIN; hospital acquired; mortality; pneumonia; telavancin

Indexed keywords

AZTREONAM; CREATININE; LINEZOLID; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TELAVANCIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CREATININE CLEARANCE; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VENTILATOR ASSOCIATED PNEUMONIA; CLINICAL TRIAL; COINFECTION; CROSS INFECTION; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; MICROBIOLOGY; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; COINFECTION; CROSS INFECTION; DOUBLE-BLIND METHOD; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84941585057     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ536     Document Type: Article

References (11)

1. VIBATIV (telavancin) Prescribing Information. Theravance Biopharma Antibiotics, Inc. December 2014. Available at: http://www.vibativ.com/. Accessed 19 March 2015.
2. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52:31-40.
3. Corey GR, Kollef MH, Shorr AF, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother 2014; 58:2030-7.
4. Rubinstein E, Cammarata S, Oliphant T,Wunderink R; the Linezolid Nosocomial Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
5. Agresti A, Caffo B. Simple and effective confidence intervals for proportions and differences of proportions resulting from adding two success and two failures. The American Statistician 2000; 54:280-8.
6. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74.
7. Piskin N, Aydemir H, Oztoprak N, et al. Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: risk factors and impact on outcomes. BMC Infect Dis 2012; 12:268.
8. Shorr AF, Kunkel MJ, Knirsch CA, Kollef MH. Predictors of mortality in catheter-related bloodstream infections. In: International Conference of the American Thoracic Society; 16-21 May 2008; Toronto, Ontario, Canada.
9. Sahm DF, Benton BM, Jones RN. Interaction of telavancin and other antimicrobial agents tested against key gram-positive species. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006; San Francisco, CA.
10. Wong SL, Sorgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere SL. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. J Clin Pharmacol 2009; 49:816-23.
11. Barriere SL, Farrell DJ, Rhomberg PR, Jones RN. Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. Diagn Microbiol Infect Dis 2014; 80:327-9.